Table 2.
Lags in drug discovery and development
Drug | Date of key enabling scientific discovery | Public? | Date of synthesis of major compound | Public? | Date of market introduction | Lag from enabling discovery to market introduction, yr. |
---|---|---|---|---|---|---|
Captopril | 1965 | Y | 1977 | N | 1981 | 16 |
Cimetidine | 1948 | Y | 1975 | N | 1977 | 29 |
Cisplatin | 1965 | Y | 1967 | Y | 1978 | 13 |
Cyclosporin | 1972 | N | 1983 | |||
EPO | 1950 | Y | 1985 | N | 1989 | 39 |
Finasteride | 1974 | Y | 1986 | N | 1992 | 18 |
Fluoxetine | 1957 | Y | 1970 | N | 1987 | 30 |
Foscarnet | 1924 | Y | 1978 | Y | 1991 | 67 |
Gemfibrozil | N | 1968 | N | 1981 | ||
Lovastatin | 1959 | Y | 1980 | N | 1987 | 28 |
Nifedipine | N | 1971 | N | 1981 | ||
Omeprazole | 1978 | N | 1989 | 11 | ||
Ondansetron | 1957 | Y | 1983 | N | 1991 | 34 |
Propranolol | 1948 | Y | 1964 | N | 1967 | 19 |
Sumatriptan | 1957 | Y | 1988 | N | 1992 | 35 |
Basic discoveries: | 11 public | 2 public | ||||
3 private | 12 private |
EPO, erythropoeitin; Y, yes; N, no.